Century Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Century Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Philadelphia
- Headquarters state / province
- Pennsylvania
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- IPSC
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001850119
- EIN
- 84-2040295
Board of directors
-
Alessandro Riva · DirectorSince 2023
-
Brent Pfeiffenberger · Director · President and CEOSince 2023
-
Cynthia M. Butitta · DirectorSince 2023
-
Daphne Quimi · DirectorSince 2023
-
Han Myung Lee · DirectorSince 2025
- Since 2023
-
Joseph Truitt · DirectorSince 2026
-
Kimberly Blackwell · DirectorSince 2023
-
Martin Patrick Murphy · DirectorSince 2025
-
Rizzuto Carlo · DirectorSince 2023
- Since 2023
Chief executives
Brent Pfeiffenberger
· President and CEO
Since December 2023
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.5%
-
99.9%
Board connections
9 of this board's directors also sit on 21 other boards.
- via Joseph Jimenez and Rizzuto Carlo
- via Daphne Quimi
- via Cynthia M. Butitta
- via Alessandro Riva
- via Alessandro Riva
- via Timothy P. Walbert
- via Brent Pfeiffenberger
- via Brent Pfeiffenberger
- via Joseph Jimenez
- via Timothy P. Walbert
- via Joseph Truitt
- via Timothy P. Walbert
- via Timothy P. Walbert
- via Kimberly Blackwell
- via Timothy P. Walbert
- via Cynthia M. Butitta
- via Joseph Jimenez
- via Timothy P. Walbert
- via Joseph Jimenez
- via Cynthia M. Butitta
- via Kimberly Blackwell
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $97,011
- 3 purchases by 2 insiders
- Sold, last 12 months
- $86,060
- 20 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 14, 2026 | Carr Douglas Officer (SVP Finance & Operations) | Open-market sale | −1,658 | $1.93 | $3,200 |
| Sep 14, 2026 | Russotti Gregory Officer (See Remarks) | Open-market sale | −2,587 | $1.93 | $4,993 |
| Sep 11, 2026 | Brent Pfeiffenberger Director, Officer (President and CEO) | Shares withheld for tax | −13,850 | $1.94 | $26,869 |
| Sep 8, 2026 | Carr Douglas Officer (SVP Finance & Operations) | Open-market sale | −254 | $2.05 | $521 |
| Sep 8, 2026 | Russotti Gregory Officer (See Remarks) | Open-market sale | −534 | $2.05 | $1,095 |
| Sep 4, 2026 | Brent Pfeiffenberger Director, Officer (President and CEO) | Shares withheld for tax | −463 | $2.11 | $977 |
| Aug 14, 2026 | Brent Pfeiffenberger Director, Officer (President and CEO) | Shares withheld for tax | −31,172 | $1.92 | $59,850 |
| Aug 3, 2026 | Carr Douglas Officer (SVP Finance & Operations) | Open-market sale | −275 | $1.98 | $544 |
| Jun 12, 2026 | Russotti Gregory Officer (See Remarks) | Open-market sale | −2,584 | $2.23 | $5,762 |
| Jun 12, 2026 | Carr Douglas Officer (SVP Finance & Operations) | Open-market sale | −1,654 | $2.23 | $3,688 |
| Jun 11, 2026 | Brent Pfeiffenberger Director, Officer (President and CEO) | Shares withheld for tax | −13,849 | $2.24 | $31,022 |
| Jun 11, 2026 | Cowan Chad Officer (Chief Scientific Officer) | Shares withheld for tax | −358 | $2.24 | $802 |
| Jun 8, 2026 | Russotti Gregory Officer (See Remarks) | Open-market sale | −524 | $2.11 | $1,106 |
| Jun 8, 2026 | Carr Douglas Officer (SVP Finance & Operations) | Open-market sale | −249 | $2.11 | $525 |
| Jun 5, 2026 | Brent Pfeiffenberger Director, Officer (President and CEO) | Shares withheld for tax | −463 | $2.13 | $986 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.